8 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
10 Aug 20
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
4:22pm
-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency,
Phase 1 healthy volunteer study continues to advance … survival. The Company expects to obtain initial Phase 1 healthy volunteer study data in Q4 2020. The phase 1b study in patients has, like many other studies
424B5
ARCT
Arcturus Therapeutics Holdings Inc
15 Apr 20
Prospectus supplement for primary offering
4:14pm
, also known as LUNAR-COV19. Under the guidance of the Singapore Health Sciences Authority (HSA), the trial plans to enroll up to 76 healthy volunteer
424B5
ARCT
Arcturus Therapeutics Holdings Inc
17 Apr 20
Prospectus supplement for primary offering
4:02pm
of the Singapore Health Sciences Authority (HSA), the trial plans to enroll up to 76 healthy volunteer adults including elderly individuals, with follow
424B5
ARCT
Arcturus Therapeutics Holdings Inc
7 Dec 20
Prospectus supplement for primary offering
5:20pm
volunteer in a Phase 1 study of ARCT-810 in a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers. The study
424B5
gej8pfn8t65e9epsdiu
28 Jul 20
Prospectus supplement for primary offering
4:17pm
424B5
qcy604c6x59xd1r5c5
30 Jul 20
Prospectus supplement for primary offering
6:01am
424B5
hhezzuaifvq67oqyjp
8 Dec 20
Prospectus supplement for primary offering
5:30pm
- Prev
- 1
- Next